Effect of levocabastine, a new H1 antagonist, in a conjunctival provocation test with allergens
Details
Serval ID
serval:BIB_DC96F26E29A0
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Effect of levocabastine, a new H1 antagonist, in a conjunctival provocation test with allergens
Journal
Journal of Allergy and Clinical Immunology
ISSN
0091-6749 (Print)
Publication state
Published
Issued date
10/1988
Volume
82
Number
4
Pages
590-4
Notes
Clinical Trial
Journal Article
Randomized Controlled Trial --- Old month value: Oct
Journal Article
Randomized Controlled Trial --- Old month value: Oct
Abstract
Levocabastine is a new, highly potent, and specific H1 antagonist. The effects of this drug, administered topically, were evaluated in a conjunctival provocation test (CPT) with allergens. CPT was performed by the instillation of one drop of allergen at increasing concentrations in the inferior conjunctival sac of each eye, alternatively, and stopped when both itching and redness of the conjunctiva were present. The concentration of allergen at this step was considered as the reaction threshold. Eleven patients, allergic to grass pollen, underwent, in winter, a first CPT without pretreatment (screening test); the CPT was then repeated twice after a 24-hour treatment, once, with a placebo, and once, with levocabastine (one drop twice a day, 0.5 mg/ml), administered in a double-blind fashion and in random order. The minimal interval between the two tests was 1 week. There was no significant difference between the thresholds determined in the two CPTs performed without medication (screening test and placebo), whereas the threshold was significantly increased (p less than 0.001) after pretreatment with levocabastine. Individually, the threshold increased in 10/11 patients (p less than 0.01). Levocabastine prevented both redness and itching. A late allergic reaction was observed by the patient in 6/11 CPTs performed after placebo treatment and 8/11 after levocabastine treatment. We conclude that, in this model of allergic conjunctivitis, levocabastine increased the conjunctival tolerance to an allergen. Further studies should help to determine the true place of this H1 antagonist in the treatment of allergic conjunctivitis.
Keywords
Allergens/immunology
Conjunctiva/*immunology
Conjunctivitis, Allergic/drug therapy/*immunology
Dose-Response Relationship, Immunologic
Female
Histamine H1 Antagonists/*pharmacology
Humans
Male
Piperidines/*pharmacology/therapeutic use
Pubmed
Web of science
Create date
28/01/2008 11:59
Last modification date
20/08/2019 16:01